04:46 AM EDT, 06/05/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Wednesday investigational drug seladelpar for the treatment of primary biliary cholangitis showed "sustained efficacy" in a two-year interim analysis of a long-term phase 3 trial.

Primary biliary cholangitis is a chronic inflammatory liver disease characterized by impaired bile flow and the accumulation of toxic bile acids in the liver.

Out of 99 participants from legacy studies who completed two years of treatment with seladelpar, 70% met the composite response endpoint, the company said. The interim results showed "rapid and sustained improvements in markers of cholestasis" that included a clinically meaningful reduction in itching, the company said.

Price: 64.22, Change: +0.06, Percent Change: +0.09